Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Expert Opin Emerg Drugs. 2023 Oct 28:1-10. doi: 10.1080/14728214.2023.2277762. Online ahead of print.NO ABSTRACTPMID:37897430 | DOI:10.1080/14728214.2023.2277762 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - October 28, 2023 Category: Drugs & Pharmacology Authors: Seng Kiong Tan Mark E Cooper Source Type: research
Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
Expert Opin Emerg Drugs. 2023 Oct 28. doi: 10.1080/14728214.2023.2277762. Online ahead of print.NO ABSTRACTPMID:37897430 | DOI:10.1080/14728214.2023.2277762 (Source: Expert Opinion on Emerging Drugs)
Source: Expert Opinion on Emerging Drugs - October 28, 2023 Category: Drugs & Pharmacology Authors: Seng Kiong Tan Mark E Cooper Source Type: research
Emerging immunotherapeutic strategies for cutaneous lupus erythematosus: an overview of recent phase 2 and 3 clinical trials
Expert Opin Emerg Drugs. 2023 Oct 20. doi: 10.1080/14728214.2023.2273536. Online ahead of print.ABSTRACTINTRODUCTION: Cutaneous lupus erythematosus (CLE) is an autoimmune disease that is clinically heterogenous and may occur with or without the presence of systemic lupus erythematosus (SLE). While existing on a spectrum, CLE and SLE present differences in their underlying pathogenesis and therapeutic responses. No new therapies have been approved in recent decades by the U.S. Food and Drug Administration for CLE, although frequently refractory to conventional therapies. There is an unmet need to develop effective drugs for...
Source: Expert Opinion on Emerging Drugs - October 20, 2023 Category: Drugs & Pharmacology Authors: Darosa Lim Julianne Kleitsch Victoria P Werth Source Type: research
Potential use of psilocybin drugs in the treatment of depression
In this study, we evaluated the efficacy and safety of psilocybin in the treatment of depression, based on pivotal randomized clinical trials. Moreover, we used findings from observational studies regarding recreational use. We also looked at ongoing clinical trials and discussed the registration status and clinical potential of the drug.EXPERT OPINION: Clinical phase I-II trials published to date reported promising results for psilocybin in the treatment of patients with major depressive disorder and treatment-resistant depression, in a relatively short time after administration. However, before psilocybin is approved for...
Source: Expert Opinion on Emerging Drugs - October 11, 2023 Category: Drugs & Pharmacology Authors: Katarzyna Śladowska Pawe ł Kawalec Tomasz Brzostek Andrzej Pilc Source Type: research
